Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.

Abstract:

BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because of hyperprogression and pseudoprogression. The aim of this study was to investigate the factors associated with tumor response and serious outcomes. METHODS:We retrospectively collected the medical records of 51 patients with advanced NSCLC who received PD-1/PD-L1 inhibitors between January 2016 and February 2018. RESULTS:The mean patient age was 63.9 years, and 72.5% (37/51) were male. Most (92.2%, 47/51) had received previous systemic treatment. The overall response rate was 21.6% (11/51). The response rate was significantly lower in patients with pleural or pericardial metastasis than in patients without pleural or pericardial metastasis (4.3% vs. 35.7%; P = 0.007). Patients with pleural or pericardial metastasis had a significantly higher rate of adverse events of any grade (91.3% vs. 50.0%; P = 0.002) and grade 3-5 adverse events (52.2% vs. 25.0%; P = 0.046). CONCLUSION:Pleural or pericardial metastasis is a significant factor affecting the efficacy and rate of adverse events in advanced NSCLC patients treated with PD-1/PD-L1 inhibitors. Clinicians should pay attention to the use of immune checkpoint inhibitors in lung cancer patients with pleural or pericardial metastasis.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Kang DH,Chung C,Kim JO,Jung SS,Park HS,Park DI,Jung SY,Park M,Lee JE

doi

10.1111/1759-7714.12877

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

1500-1508

issue

11

eissn

1759-7706

issn

1759-7714

journal_volume

9

pub_type

杂志文章
  • Metastasis in the subcarinal lymph node with unknown primary tumor.

    abstract::A 59-year-old man with previous anaplastic large cell T-cell lymphoma stage 3A was admitted with an isolated positron emission tomography(PET)-positive spot in a subcarinal lymph node. Diagnosis was achieved with endobronchial ultrasound-guided fine-needle aspiration demonstrating a well-differentiated squamous cell c...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2010.00039.x

    authors: Eckardt J,Olsen KE,Petersen H

    更新日期:2011-05-01 00:00:00

  • Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).

    abstract:BACKGROUND:Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dos...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12407

    authors: Fukuda M,Shimada M,Kitazaki T,Nagashima S,Hashiguchi K,Ebi N,Takayama K,Nakanishi Y,Semba H,Harada T,Seto T,Okamoto I,Ichinose Y,Sugio K

    更新日期:2017-01-01 00:00:00

  • Inhibition of miR-24 suppresses malignancy of human non-small cell lung cancer cells by targeting WWOX in vitro and in vivo.

    abstract:BACKGROUND:We investigated the effect of micro-RNA 24 (miR-24) and WWOX on non-small cell lung cancer (NSCLC) cell proliferation and migration in vitro and in vivo. METHODS:We performed bioinformatics analysis and 3' untranslated region luciferase assay to investigate the direct target of miR-24. Proliferation, apopto...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12824

    authors: Wang XH,Gan CZ,Xie JY

    更新日期:2018-12-01 00:00:00

  • Radiological-pathological correlation of malignant teratoma with liposarcomatous transformation: Proven by repeated transthoracic needle biopsy.

    abstract::A mediastinal germ cell tumor with a sarcomatous component is extremely rare and is accompanied by a poor prognosis. Clinical and radiologic diagnosis is very difficult. Herein, we report a rare case of anterior mediastinal malignant teratoma containing a growing liposarcomatous component and detail the diagnostic pro...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12553

    authors: Lee HJ,Seon HJ,Choi YD

    更新日期:2018-01-01 00:00:00

  • Circular RNA 0007255 regulates the progression of breast cancer through miR-335-5p/SIX2 axis.

    abstract:BACKGROUND:Breast cancer (BC) is a common cancer in women worldwide. Emerging evidence has indicated that circular RNA hsa-circ_0007255 (circ_0007255) is a prognostic mediator in BC progression. However, the functional role of circ_0007255 needs to be determined. METHODS:The expression of circ_0007255, microRNA (miR)-...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13306

    authors: Jia Q,Ye L,Xu S,Xiao H,Xu S,Shi Z,Li J,Chen Z

    更新日期:2020-03-01 00:00:00

  • Analysis of giant thoracic neoplasms: Correlations between imaging, pathology and surgical management.

    abstract:BACKGROUND:A giant thoracic neoplasm is extremely rare and poorly understood. Our systemic study introduced computed tomography angiography (CTA) with three-dimensional (3D) reconstruction imaging and evaluated correlations between imaging, pathology, and surgical management. METHODS:Data from 45 patients undergoing s...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12448

    authors: Feng Z,Li M,Liu F,Peng Y,Ren W,Xie H,Peng Z

    更新日期:2017-09-01 00:00:00

  • Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.

    abstract:BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13241

    authors: Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

    更新日期:2020-01-01 00:00:00

  • Soluble fms-like tyrosine kinase-1-enriched exosomes suppress the growth of small cell lung cancer by inhibiting endothelial cell migration.

    abstract:BACKGROUND:Previous studies have reported that soluble fms-like tyrosine kinase-1 (sFlt-1) possesses anti-tumor effects by inhibiting angiogenesis in many cancers. Exosomes can be engineered as delivery vehicles for transferring functional biomolecules, such as proteins, lipids, and nucleic acids (DNA, mRNA, and miRNA)...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13175

    authors: Hao D,Li Y,Zhao G,Zhang M

    更新日期:2019-10-01 00:00:00

  • Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

    abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12275

    authors: Sun H,Sun X,Zhai X,Guo J,Liu Y,Ying J,Wang Z

    更新日期:2016-01-01 00:00:00

  • Effect of spider venom on inhibition proliferation of TE13 cells in vivo and in vitro.

    abstract:BACKGROUND:The aim of this study was to evaluate the cytotoxic and antitumor activity of spider venom (SV). METHODS:Cell proliferation and cytotoxicity were determined by 3 H-methyl thymidine incorporation ([3 H]-TDR) assay. DNA fragmentation and cell cycle kinetics were analyzed by FACS. In vivo inhibition of tumor s...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12020

    authors: Gao L,Zhang J,Liu X,Zhao M,Li L,Liu X,Zhao B

    更新日期:2013-08-01 00:00:00

  • Osimertinib-induced severe interstitial lung disease: A case report.

    abstract::Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old ma...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13127

    authors: Fan M,Mo T,Shen L,Yang L

    更新日期:2019-07-01 00:00:00

  • Uniportal video-assisted thoracoscopic left pneumonectomy: Retrospective analysis of eighteen consecutive patients from a single center.

    abstract:BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13728

    authors: Li J,Xue Q,Gao Y,Mao Y,Zhao J,Gao S

    更新日期:2021-01-06 00:00:00

  • Epidemiology of lung cancer in China.

    abstract:BACKGROUND:Lung cancer is the most common cancer and the leading cause of cancer death in China. Along with socioeconomic development, environmental problems have intensified and the burden of lung cancer continues to increase. METHODS:In this study, national cancer registry data was used for evaluating incidence, mor...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12169

    authors: Chen W,Zheng R,Zeng H,Zhang S

    更新日期:2015-03-01 00:00:00

  • Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm.

    abstract:BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13336

    authors: Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS

    更新日期:2020-04-01 00:00:00

  • Intercostal hemangioma presenting with multiple metastasized lung nodules caused by pneumonia.

    abstract::Multiple lung nodules caused by pneumonia are a rare presentation in intercostal hemangioma. We experienced a case with intercostal hemangioma that presented with multiple metastasized lung nodules caused by pneumonia, which had previously been misdiagnosed as sarcoma six months earlier. The patient was treated for pn...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2010.00024.x

    authors: Mei L,Shi H,Che G

    更新日期:2010-11-01 00:00:00

  • Chinese expert consensus on diagnosis and management of acquired respiratory-digestive tract fistulas.

    abstract::Acquired respiratory-digestive tract fistulas occur with abnormal communication between the airways and digestive tract, causing the interflow of gas and liquid. Despite advances in surgical methods and the development of multimodal therapy in recent years, patients with acquired respiratory-digestive tract fistulas c...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12856

    authors: Wang H,Ke M,Li W,Wang Z,Li H,Cong M,Zeng Y,Chen L,Lai G,Xie B,Zhang N,Li W,Zhou H,Wang X,Lin D,Zhou Y,Zhang H,Li D,Song X,Wang J,Wu S,Tao M,Sha Z,Tan Q,Han X,Luo L,Ma H,Wang Z

    更新日期:2018-11-01 00:00:00

  • Use of glucocorticoids in the management of immunotherapy-related adverse effects.

    abstract::Immune checkpoint inhibitors (ICIs) activate host antitumor immunity to kill tumor cells. However, ICI therapy may be accompanied by a series of immunotherapy-related adverse effects (irAEs) caused by activated autoreactive T cells. Glucocorticoids are the mainstream therapy for irAEs. However, the usage, dosage and c...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13589

    authors: Wang H,Zhou J,Guo X,Li Y,Duan L,Si X,Zhang L

    更新日期:2020-10-01 00:00:00

  • CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.

    abstract::ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12617

    authors: Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

    更新日期:2018-05-01 00:00:00

  • Short-term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm.

    abstract:INTRODUCTION:VATS pulmonary segmentectomy is increasingly proposed as a parenchyma-sparing resection for tumors smaller than 2 cm in diameter. The aim of this study was to compare short-term oncological results and local control in solid non-small cell lung cancers (NSCLCs) <2 cm surgically treated by intentional VATS ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13766

    authors: Darras M,Ojanguren A,Forster C,Zellweger M,Perentes JY,Krueger T,Gonzalez M

    更新日期:2020-12-03 00:00:00

  • Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.

    abstract:BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13526

    authors: Kasahara N,Imai H,Naruse I,Tsukagoshi Y,Kotake M,Sunaga N,Kaira K,Maeno T,Asao T,Hisada T

    更新日期:2020-08-01 00:00:00

  • Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes.

    abstract:BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13226

    authors: Meijer TWH,Looijen-Salamon MG,Lok J,van den Heuvel M,Tops B,Kaanders JHAM,Span PN,Bussink J

    更新日期:2019-12-01 00:00:00

  • Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.

    abstract:BACKGROUND:Currently, there are no standard regimens for metastatic breast cancer patients (MBC) who have failed ≥ 3 chemotherapy treatments. The aim of this study was to assess whether weekly low-dose bevacizumab-based regimens were well tolerated and would improve efficacy in MBC patients who had failed numerous ther...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12627

    authors: Zhai X,Hong R,Fan Y,Yuan P,Wang J,Sang D,Chen J,Zhao C,Ou K,Ma F,Xu B

    更新日期:2018-05-01 00:00:00

  • Thoracoscopic completion right lower lobectomy after anteromedial basilar segmentectomy in early-stage lung cancer.

    abstract::This report describes the surgical management of a male patient with early-stage lung cancer who underwent thoracoscopic completion right lower lobectomy after previously undergoing sublobar resection for multifocal ground glass nodules of the lung. Perioperative considerations associated with the management of dense ...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13036

    authors: Liu YW,Chou SH,Hung JY,Kao CN,Chang PC

    更新日期:2019-05-01 00:00:00

  • Management of immune checkpoint inhibitor-related dermatologic adverse events.

    abstract::Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pru...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13275

    authors: Si X,He C,Zhang L,Liu X,Li Y,Wang H,Guo X,Zhou J,Duan L,Wang M,Zhang L

    更新日期:2020-02-01 00:00:00

  • Attempt of peripheral nerve reconstruction during lung cancer surgery.

    abstract:BACKGROUND:Vagus nerve and recurrent laryngeal nerve (RLN) injury are not rare complications of lung cancer surgery and can cause lethal consequences. Until now, no optimal method other than paying greater attention during surgery has been available. METHODS:Four patients underwent lung surgery that involved RLN or va...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12619

    authors: Li H,Hu Y,Huang J,Yang Y,Xing K,Luo Q

    更新日期:2018-05-01 00:00:00

  • The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.

    abstract:BACKGROUND:Despite recent advances in treating non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK-positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK-positive NSCLC. METHODS:Between 2011 and 2018, a total of 14 ALK-positive NSCLC pat...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13195

    authors: Heo JY,Park C,Keam B,Ock CY,Kim M,Kim TM,Kim DW,Kim SH,Kim YJ,Lee JS,Heo DS

    更新日期:2019-11-01 00:00:00

  • Expression of Pax8 is decreased and bortezomib does not increase the iodine uptake in thyroid carcinoma cells.

    abstract::Fundamental treatment for papillary thyroid carcinoma (PTC) involves total or subtotal thyroidectomy. Iodine-131 ((131)I) is routinely utilized to target remnant thyroid cancer and metastasis after thyroidectomy. The effectiveness of other therapeutic modalities remains unsatisfactory; thus, these patients have a poor...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12277

    authors: Wang HJ,Yao JM,Zhang ZW,Zhao JY,Shang HX,Liao L,Dong JJ

    更新日期:2015-11-01 00:00:00

  • Right upper lobectomy in lung cancer with double aortic arch: A case report.

    abstract::Double aortic arch (DAA) is a rare congenital anomaly of the heart and aorta in which a vascular ring that surrounds the trachea and esophagus is formed. In most patients, respiratory distress and dysphagia develop in childhood, and asymptomatic adult patients are rarely known. Herein, we describe a patient with lung ...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13545

    authors: Kawamoto N,Okita R,Inokawa H,Hayashi M,Furukawa M,Okada M,Okabe K

    更新日期:2020-08-01 00:00:00

  • Sebaceous-like clear cell changes in primary lung cancer.

    abstract::We examined two cases of primary lung cancer with sebaceous-like clear cells (SLCCs), defined as clear carcinoma cells with microvacuolated cytoplasm and centrally located nuclei, which were selected from among 281 surgical/autopsy cases of lung cancer (2/281, 0.7%). Both cases were higher stage (stage IIA and IIIA), ...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12004

    authors: Matsukuma S,Obara K,Kono T,Takeo H,Sato K

    更新日期:2013-11-01 00:00:00

  • EGFR exon 19-deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non-small cell lung cancer.

    abstract:BACKGROUND:Epidermal growth factor receptor (EGFR) activating mutations are usually associated with DNA damage repair (DDR) deficiency. However, the precise mechanism has remained elusive. In this study, we aimed to investigate whether EGFR exon 19 deletion mutation downstream signals contributed to DDR deficiency by d...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13253

    authors: Zhang L,Pradhan B,Guo L,Meng F,Zhong D

    更新日期:2020-02-01 00:00:00